Abstract
15631 Background: Second-line chemotherapy is widely used in advanced pancreatic cancer. However, only little data exist concerning the question which patients might benefit from second-line therapy. We intended to identify prognostic factors for time to second progression and rest survival under second-line chemotherapy of advanced pancreatic cancer. Methods: We performed a retrospective cohort study of 78 patients who started palliative chemotherapy at our department from January 2004 to June 2006 due to advanced adenocarcinoma of the pancreas. This analysis focusses on 46 patients who experienced progression under first-line therapy. Results: In multivariate analyses time to first progression below 6 months and elevated LDH at the time of diagnosis were shown to be strong and highly significant independent prognostic factors for time to second progression and residual survival. For patients with time to first progression shorter than 6 months the prognosis was poor with a median residual survival of 4....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
